Intraokulare Entzündungen bei Brolucizumab-Anwendung: Patientenmanagement – Diagnose – Therapie

The anti-vascular endothelial growth factor (anti-VEGF) agent brolucizumab has been approved in the USA in October 2019 and in Europe in February 2020 for the treatment of neovascular age-related macular degeneration (nAMD). The approval was based on the randomized, double-blind phase III studies HA...

Descripción completa

Detalles Bibliográficos
Autores principales: Holz, F. G., Heinz, C., Wolf, A., Hoerauf, H., Pleyer, U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Übersichten
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935813/
https://www.ncbi.nlm.nih.gov/pubmed/33555415
http://dx.doi.org/10.1007/s00347-021-01321-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935813/
https://www.ncbi.nlm.nih.gov/pubmed/33555415
http://dx.doi.org/10.1007/s00347-021-01321-8

Ejemplares similares